Investing in fundamentals is all about getting out ahead of the expected news. While the data we have received to date is early, it is so positive that we can project where it is going if you compare it to the preclinical data.
The difference in efficacy between CU6 and other competing companies is not the isotope used - both 255Ac and 67Cu kill cells well, it is the SAR-bisPSMA backbone. This holds onto the isotope better (SAR), but more importantly the bisPSMA is able to target the cancer cells more effectively (10x from the preclinical data). I would expect that a 255Ac SAR-bisPSMA equivalent would work as well as 67Cu, although you would lose the other advantages the 63/67Cu pair gives.
CU6 - Media and Industry News, page-27
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.83 |
Change
-0.020(0.29%) |
Mkt cap ! $2.187B | |||
| Open | High | Low | Value | Volume |
| $6.83 | $7.05 | $6.58 | $11.93M | 1.755M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1461 | $6.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.90 | 3341 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |